Provided by Tiger Trade Technology Pte. Ltd.

Carlisle

346.58
-9.9500-2.79%
Post-market: 346.580.00000.00%19:35 EDT
Volume:3.66M
Turnover:1.27B
Market Cap:13.76B
PE:19.93
High:355.30
Open:352.50
Low:343.06
Close:356.53
52wk High:432.91
52wk Low:293.43
Shares:39.71M
Float Shares:39.20M
Volume Ratio:9.89
T/O Rate:9.34%
Dividend:4.40
Dividend Rate:1.27%
EPS(TTM):17.39
EPS(LYR):17.12
ROE:39.18%
ROA:10.81%
PB:8.51
PE(LYR):20.25

Loading ...

Carlisle: Strong Quarter and Raised Sales Guidance Offset by Margin Pressures and Limited Near-Term Catalysts, Justifying Hold Rating

TIPRANKS
·
Jul 30

CSL Stock And QBE Shares For Dividend Income Above 3%

Simply Wall St.
·
Jul 30

Carlisle Companies Inc : Raymond James Cuts Target Price to $410 from $425

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

Simply Wall St.
·
Jul 30

Analysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF) and Polynovo (OtherCALZF)

TIPRANKS
·
Jul 30

Carlisle Companies Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Carlisle FY26 Q2 Adjusted EPS Rises 12% to $7.03; Revenue Climbs 8% to $1.57 Billion

Reuters
·
Jul 30

Carlisle reports Q2 EPS $7.03 vs $6.27 last year

TIPRANKS
·
Jul 30

Carlisle raises FY26 revenue view to mid-single-digit growth

TIPRANKS
·
Jul 30

Carlisle Companies Q2 Adj. EPS $7.03 Beats $6.35 Estimate, Sales $1.600B Beat $1.476B Estimate

Benzinga Earnings
·
Jul 30

Carlisle Companies Q2 EPS USD 6.36

Reuters
·
Jul 30

Carlisle Companies Reports Second Quarter Results

THOMSON REUTERS
·
Jul 30

Carlisle Companies Q2 Net Income USD 255.2 Million

THOMSON REUTERS
·
Jul 30

Carlisle Companies Inc: Increasing Share Repurchase Target to $1.2 Bln for 2026

THOMSON REUTERS
·
Jul 30

Carlisle Companies Inc: Increasing FY 2026 Revenue Outlook to Mid-Single-Digit Growth with Flat Adj. Ebitda Margin

THOMSON REUTERS
·
Jul 30

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

MT Newswires Live
·
Jul 29

CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

MT Newswires Live
·
Jul 28

CSL Stock And 2 More Australian Income Shares For Steady Dividends

Simply Wall St.
·
Jul 27

CSL Stock And 2 Australian Dividend Shares For Reliable Income

Simply Wall St.
·
Jul 25